Achievements
WP1 Report: creation of an online platform for data and protocols sharing
We have created an organic and organized platform to share the protocols and all data collected.
This will allow us to build a robust and replicable set of uniformed protocols and techniques to deeply study and understand senescence in the different models such as cancer (Alimonti Lab), ageing and mitochondrial stress (Auwerx lab), Kidney disease (Cippà Lab) and heart disease (Barile lab).
WP2 Report: Cross-validation of senostatic and senolytic compounds
WP2 consists of the combination of two innovative platforms aimed at identifying compounds targeting senescence (Alimonti’s lab) and interfering with lifespan in C. elegans (Auwerx’s lab) and in the cross-validation of the most promising compounds that could be effective in a complex biological system such as aging and cancer.
WP3 Report: testing newly identified compounds
WP3 was successfully completed, testing novel compounds identified in WP2 in models of cancer, tissue injury, and metabolic disorders. The efficacy was assessed through RNA sequencing. Compounds were evaluated in metabolic syndrome, kidney injury, cardiac senescence, and prostate cancer models.
Publications
Prizes
June 2024 (Gleditsia)
Nephrology Laboratory guided by Professor Cippà, won the poster prize for the project entitled “Identification of a naturally derived senolytic compound to prevent kidney aging”.
December 2023 (Hanekenium and ABT263 data)
Nephrology Laboratory guided by Professor Cippà, won the ERA prize for the presentation entitled “Identification of a novel senolytic compound to prevent chronic kidney injury and fibrosis”.
